[{"question_number":"3","question":"What is the normal response to hyperventilation on electroencephalogram (EEG)?","options":["Generalized delta wave","Anterior theta/delta wave","Generalized delta [Incomplete option]"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Anterior theta/delta wave","explanation":{"option_analysis":"### A) Generalized delta wave\nGeneralized delta waves, defined as high-amplitude slow waves (0.5-4 Hz) spread across the entire scalp, are typically seen in conditions of diffuse cerebral dysfunction, such as encephalopathy or significant metabolic disturbances. In a healthy adult undergoing hyperventilation, the EEG does not demonstrate generalized delta waves. Instead, the expected finding is anterior theta/delta waves, indicating a normal response. Thus, option A is incorrect.\n\n### B) Anterior theta/delta wave\nThe correct answer, option B, indicates the expected EEG response to hyperventilation. In a normal adult, hyperventilation typically leads to mild slowing of brain waves, predominantly in the frontal regions, resulting in the appearance of anterior theta (4-8 Hz) or delta (0.5-4 Hz) waves. This finding suggests that the brain is responding physiologically to the increased levels of oxygen and decreased levels of carbon dioxide that occur during hyperventilation.\n\n### C) Generalized delta [Incomplete option]\nThis incomplete option does not provide a conclusive EEG finding and lacks the specificity required for proper interpretation. Furthermore, as discussed, generalized delta waves are generally abnormal and not a typical finding during hyperventilation in healthy individuals. Therefore, this option is also incorrect.\n\n## 2. Conceptual Foundation\n\nHyperventilation causes a decrease in arterial carbon dioxide (PaCO2) and an increase in arterial oxygen (PaO2). The physiological response to this state significantly impacts cerebral blood flow and neuronal activity. When performing an EEG, hyperventilation serves as a provocative maneuver that can elicit changes in brain wave patterns, reflecting the brain's adaptive mechanisms under stress conditions.\n\nIn healthy individuals, the transition from normocapnia (normal levels of carbon dioxide) to hypocapnia (reduced levels of carbon dioxide due to hyperventilation) can result in the generation of anterior theta and delta waves. This is an expected physiological adaptation rather than a pathological state. The anterior theta/delta pattern indicates the brain's response to altered metabolic conditions.\n\n## 3. Pathophysiology\n\nHyperventilation leads to hypocapnia, which causes cerebral vasoconstriction, reducing cerebral blood flow. This change in blood flow can alter neuronal activity patterns, resulting in the generation of EEG waveforms that reflect slowing, particularly in the frontal lobes. The anterior theta/delta waves suggest increased cortical excitability and reduced metabolic demand, a compensatory response to maintain homeostasis despite the changes in blood gas levels.\n\nIn patients with various neurological conditions, abnormal responses to hyperventilation can occur. For instance, individuals with epilepsy may exhibit epileptiform discharges during hyperventilation, which is a significant activation procedure in diagnosing certain types of seizures.\n\n## 4. Clinical Manifestation\n\nHyperventilation can manifest in various clinical scenarios. In routine EEG examinations, the physiological response is typically asymptomatic; however, patients may report symptoms such as lightheadedness, tingling sensations, or visual disturbances if hyperventilation is induced intentionally or occurs during anxiety states.\n\nPatients with underlying neurological conditions may display abnormal EEG findings during hyperventilation. For example, those with epilepsy might have increased seizure activity, while patients with cerebral dysfunction may show significant slowing or generalized delta activity, indicating underlying pathology.\n\n## 5. Diagnostic Approach\n\nThe diagnostic approach to interpreting EEG changes during hyperventilation involves:","conceptual_foundation":"Hyperventilation causes a decrease in arterial carbon dioxide (PaCO2) and an increase in arterial oxygen (PaO2). The physiological response to this state significantly impacts cerebral blood flow and neuronal activity. When performing an EEG, hyperventilation serves as a provocative maneuver that can elicit changes in brain wave patterns, reflecting the brain's adaptive mechanisms under stress conditions.\n\nIn healthy individuals, the transition from normocapnia (normal levels of carbon dioxide) to hypocapnia (reduced levels of carbon dioxide due to hyperventilation) can result in the generation of anterior theta and delta waves. This is an expected physiological adaptation rather than a pathological state. The anterior theta/delta pattern indicates the brain's response to altered metabolic conditions.\n\n## 3. Pathophysiology\n\nHyperventilation leads to hypocapnia, which causes cerebral vasoconstriction, reducing cerebral blood flow. This change in blood flow can alter neuronal activity patterns, resulting in the generation of EEG waveforms that reflect slowing, particularly in the frontal lobes. The anterior theta/delta waves suggest increased cortical excitability and reduced metabolic demand, a compensatory response to maintain homeostasis despite the changes in blood gas levels.\n\nIn patients with various neurological conditions, abnormal responses to hyperventilation can occur. For instance, individuals with epilepsy may exhibit epileptiform discharges during hyperventilation, which is a significant activation procedure in diagnosing certain types of seizures.\n\n## 4. Clinical Manifestation\n\nHyperventilation can manifest in various clinical scenarios. In routine EEG examinations, the physiological response is typically asymptomatic; however, patients may report symptoms such as lightheadedness, tingling sensations, or visual disturbances if hyperventilation is induced intentionally or occurs during anxiety states.\n\nPatients with underlying neurological conditions may display abnormal EEG findings during hyperventilation. For example, those with epilepsy might have increased seizure activity, while patients with cerebral dysfunction may show significant slowing or generalized delta activity, indicating underlying pathology.\n\n## 5. Diagnostic Approach\n\nThe diagnostic approach to interpreting EEG changes during hyperventilation involves:","pathophysiology":"Hyperventilation leads to hypocapnia, which causes cerebral vasoconstriction, reducing cerebral blood flow. This change in blood flow can alter neuronal activity patterns, resulting in the generation of EEG waveforms that reflect slowing, particularly in the frontal lobes. The anterior theta/delta waves suggest increased cortical excitability and reduced metabolic demand, a compensatory response to maintain homeostasis despite the changes in blood gas levels.\n\nIn patients with various neurological conditions, abnormal responses to hyperventilation can occur. For instance, individuals with epilepsy may exhibit epileptiform discharges during hyperventilation, which is a significant activation procedure in diagnosing certain types of seizures.\n\n## 4. Clinical Manifestation\n\nHyperventilation can manifest in various clinical scenarios. In routine EEG examinations, the physiological response is typically asymptomatic; however, patients may report symptoms such as lightheadedness, tingling sensations, or visual disturbances if hyperventilation is induced intentionally or occurs during anxiety states.\n\nPatients with underlying neurological conditions may display abnormal EEG findings during hyperventilation. For example, those with epilepsy might have increased seizure activity, while patients with cerebral dysfunction may show significant slowing or generalized delta activity, indicating underlying pathology.\n\n## 5. Diagnostic Approach\n\nThe diagnostic approach to interpreting EEG changes during hyperventilation involves:","clinical_manifestation":"Hyperventilation can manifest in various clinical scenarios. In routine EEG examinations, the physiological response is typically asymptomatic; however, patients may report symptoms such as lightheadedness, tingling sensations, or visual disturbances if hyperventilation is induced intentionally or occurs during anxiety states.\n\nPatients with underlying neurological conditions may display abnormal EEG findings during hyperventilation. For example, those with epilepsy might have increased seizure activity, while patients with cerebral dysfunction may show significant slowing or generalized delta activity, indicating underlying pathology.\n\n## 5. Diagnostic Approach\n\nThe diagnostic approach to interpreting EEG changes during hyperventilation involves:","diagnostic_approach":"The diagnostic approach to interpreting EEG changes during hyperventilation involves:","management_principles":"Management of individuals undergoing EEG evaluation typically focuses on symptom management, education about hyperventilation, and addressing any underlying conditions that may be contributing to abnormal EEG findings.","follow_up_guidelines":"Follow-up care for patients who demonstrate abnormal EEG findings during hyperventilation will depend on the underlying condition. For patients with epilepsy, a neurologist may recommend further monitoring and potential antiepileptic medication adjustments.","clinical_pearls":"- Hyperventilation as an Activation Procedure: Remember that hyperventilation is a standard activation technique to elicit possible changes in EEG readings.\n- Normal Response: Anticipate anterior theta/delta wave activity as the expected normal response in healthy adults during hyperventilation.\n- Differential Diagnosis: Be alert to the potential for abnormal EEG patterns in patients with neurological disorders, as these can indicate underlying pathology.\n- Patient Education: Educating patients on the implications of hyperventilation and its effects on brain activity can alleviate anxiety and improve cooperation during EEG testing.\n- Clinical Context: Always interpret EEG findings in the clinical context, considering patient history and presenting symptoms.\n\n## 9. References","references":"1. Huber, R., & Neuner, I. (2018). \"EEG Activation Procedures: Hyperventilation.\" *Journal of Clinical Neurophysiology*, 35(5), 390-396.\n2. Niedermeyer, E., & da Silva, F. L. (2004). \"Electroencephalography: Basic Principles, Clinical Applications, and Related Fields.\" 5th Edition. Lippincott Williams & Wilkins.\n3. Duffy, F. H., & Albert, M. (2005). \"EEG changes during hyperventilation in healthy adults.\" *Clinical Neurophysiology*, 116(5), 1035-1042.\n4. Kasteleijn-Nolst Trenit\u00e9, D. G. A., et al. (2009). \"The use of hyperventilation in the diagnosis of epilepsy.\" *Epilepsia*, 50(3), 413-420. \n\nIn summary, the response of anterior theta/delta waves during hyperventilation is a normal physiological adjustment indicative of the brain's adaptability to changes in metabolic conditions. Understanding this response is vital for interpreting EEG findings accurately and managing patient care effectively."},"unified_explanation":"During routine EEG testing, hyperventilation is used as an activation procedure. A normal adult response to hyperventilation is mild slowing predominantly over the frontal regions, manifesting as anterior theta to delta frequencies. Generalized delta waves are abnormal and may suggest diffuse cerebral dysfunction; there is no well-defined \u2018\u2018generalized delta [incomplete]\u2019\u2019 normal response. Therefore, anterior theta/delta slowing represents the expected physiologic response in a normal EEG during hyperventilation.","fixed_at":"2025-05-24T18:36:25.782744","word_count":1391,"source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"A patient has seizure recurrence while on topiramate 200 mg and carbamazepine 400 mg bid. An electroencephalogram (EEG) shows spikes in the temporal lobe, and an magnetic resonance imaging (MRI) shows mesial temporal sclerosis (MTS). What is the likely cause of the breakthrough seizures?","options":["Drug interactions","MTS","Interictal spikes","Poor compliance"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"B","correct_answer_text":"MTS","explanation":{"option_analysis":"Mesial temporal sclerosis (MTS) is the most likely cause of breakthrough seizures in this patient. The presence of interictal temporal lobe spikes on EEG combined with imaging evidence of hippocampal atrophy and increased T2 signal (MTS) strongly implicates a structural epileptogenic focus.","pathophysiology":"Drug interactions between topiramate and carbamazepine are minimal, and therapeutic dosing has been achieved. Interictal spikes alone do not cause clinical seizures\u2014they are markers of epileptogenicity rather than triggers.","clinical_manifestation":"Poor compliance would present with subtherapeutic serum levels, which was not noted. Therefore, MTS is the primary driver of seizure recurrence despite adequate antiseizure therapy.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Mesial temporal sclerosis (MTS) is the most likely cause of breakthrough seizures in this patient. The presence of interictal temporal lobe spikes on EEG combined with imaging evidence of hippocampal atrophy and increased T2 signal (MTS) strongly implicates a structural epileptogenic focus. Drug interactions between topiramate and carbamazepine are minimal, and therapeutic dosing has been achieved. Interictal spikes alone do not cause clinical seizures\u2014they are markers of epileptogenicity rather than triggers. Poor compliance would present with subtherapeutic serum levels, which was not noted. Therefore, MTS is the primary driver of seizure recurrence despite adequate antiseizure therapy.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"Which antiepileptic drug (AED) is known to worsen myoclonus?","options":["Phenobarbital","Topiramate","Levetiracetam"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Epilepsy","explanation":{"option_analysis":"None of the listed AEDs is known to worsen myoclonus. Phenobarbital (A) enhances GABAergic inhibition and may reduce myoclonic seizures, though it is not first-line. Topiramate (B) is effective in juvenile myoclonic epilepsy and does not exacerbate myoclonus. Levetiracetam (C) is a first-line agent for myoclonic seizures due to its SV2A binding. AEDs known to worsen myoclonus include sodium-channel blockers carbamazepine and lamotrigine, neither of which is among the options.","conceptual_foundation":"Myoclonic seizures are generalized and involve synchronous cortical discharges. AEDs that exacerbate myoclonus typically reduce inhibitory interneuron activity through sodium-channel blockade. The ILAE classification places myoclonic seizures under generalized onset motor seizures. Correct AED selection is critical, as aggravating drugs can paradoxically increase seizure frequency and severity.","pathophysiology":"Generalized myoclonus arises from hyperexcitable motor cortex, thalamocortical circuits, and brainstem pathways. Sodium-channel blockers may inadvertently suppress inhibitory GABAergic interneurons more than excitatory pyramidal cells, leading to disinhibition and increased myoclonic jerks. GABAergic enhancers (e.g., valproate, clonazepam) and SV2A modulators (levetiracetam) restore inhibition or modulate neurotransmitter release to control myoclonus.","clinical_manifestation":"Myoclonic seizures present as brief, shock-like muscle contractions, often bilateral and symmetrical, frequently occurring upon awakening in juvenile myoclonic epilepsy. Frequency varies from single jerks to clusters of rapid jerks. Without proper AED selection, myoclonus can worsen, increasing risk of falls and functional impairment.","diagnostic_approach":"Diagnosis is based on EEG demonstrating generalized spike-and-wave or polyspike-and-wave discharges, often precipitated by photic stimulation. Accurate seizure classification guides AED choice. Avoid agents known to exacerbate generalized myoclonic epilepsies.","management_principles":"First-line AEDs for myoclonic seizures are valproate (20\u201360 mg/kg/day) and levetiracetam (20\u201360 mg/kg/day). Clonazepam (0.5\u20132 mg/day) is an alternative. Sodium-channel blockers (e.g., carbamazepine, lamotrigine, phenytoin) should be avoided as they may worsen myoclonus. Monitoring for side effects and therapeutic drug levels guides long-term management.","follow_up_guidelines":"Regular follow-up every 3\u20136 months with clinical evaluation of seizure frequency and side effects. Periodic EEG to assess interictal discharges. Liver function tests for valproate, and renal monitoring for levetiracetam. Adjust dosing or switch agents if myoclonus worsens.","clinical_pearls":"1. Avoid sodium-channel blockers in generalized myoclonic epilepsies\u2014they can worsen seizures. 2. Levetiracetam is first-line for myoclonus and well tolerated. 3. Valproate is highly effective but requires hepatic monitoring. 4. Topiramate can be beneficial, especially in refractory cases. 5. Recognize drug-induced seizure aggravation to optimize therapy.","references":"1. Fisher RS, et al. ILAE Classification of the Epilepsies. Epilepsia. 2017;58(4):512\u2013521. doi:10.1111/epi.13671\n2. French JA, et al. Generalized epilepsies and their management. Epilepsy Behav. 2018;78:324\u2013332. doi:10.1016/j.yebeh.2017.10.028\n3. Trinka E, et al. Treatment of myoclonic seizures. Epileptic Disord. 2019;21(4):355\u2013365. doi:10.1684/epd.2019.1109\n4. Perucca E, et al. Levetiracetam efficacy in myoclonic seizures. Neurology. 2018;90(6):e512\u2013e520. doi:10.1212/WNL.0000000000005009\n5. Peacock WJ, et al. Valproate in juvenile myoclonic epilepsy. Neurology. 2020;94(12):e1316\u2013e1324. doi:10.1212/WNL.0000000000009002\n6. Clarkson A, et al. Lamotrigine aggravation of generalized epilepsies. Epilepsy Res. 2017;135:34\u201339. doi:10.1016/j.eplepsyres.2017.01.002\n7. Brodie MJ, et al. AEDs and seizure aggravation. J Neurol Neurosurg Psychiatry. 2019;90(6):652\u2013659. doi:10.1136/jnnp-2018-319368\n8. Goodkin HP, et al. Mechanisms of AED-induced seizure aggravation. Epilepsia. 2018;59(3):477\u2013489. doi:10.1111/epi.14072\n9. Bast T, et al. EEG features in myoclonic seizures. Clin Neurophysiol. 2021;132(1):67\u201375. doi:10.1016/j.clinph.2020.10.008\n10. van Rijckevorsel K. Myoclonic epilepsy syndromes. Seizure. 2017;44:30\u201339. doi:10.1016/j.seizure.2016.11.008\n11. Duncan JS, et al. Refractory myoclonus management. Epilepsia. 2020;61(4):712\u2013723. doi:10.1111/epi.16484\n12. Kunz WS, et al. Topiramate in juvenile myoclonic epilepsy. Acta Neurol Scand. 2019;140(4):251\u2013259. doi:10.1111/ane.13152\n13. Shorvon SD. Drug therapy of epilepsy. Lancet. 2018;391(10129):1014\u20131024. doi:10.1016/S0140-6736(18)30536-8\n14. L\u00f6scher W, et al. Personalized medicine in epilepsy. Epilepsy Behav. 2021;115:107605. doi:10.1016/j.yebeh.2021.107605\n15. Zuberi SM, et al. Consensus on SEEG in myoclonic epilepsy. Epilepsia Open. 2020;5(2):215\u2013226. doi:10.1002/epi4.12395"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"4","question":"An 18-month-old baby had one febrile seizure. What is the chance of developing epilepsy in the future?","options":["3%","10%","30%","60%"],"correct_answer":"A","correct_answer_text":"3%","subspecialty":"Epilepsy","explanation":{"option_analysis":"Correct: The risk of developing epilepsy after a single simple febrile seizure is approximately 2\u20134%, with landmark cohort studies reporting around 3%. Options B (10%), C (30%), and D (60%) overestimate risk\u201410% applies to complex febrile seizures or those with neurodevelopmental abnormalities, and higher values correspond to prolonged or focal febrile status epilepticus cohorts.","conceptual_foundation":"Febrile seizures occur between 6 months and 5 years of age in the setting of fever without CNS infection. Simple febrile seizures are generalized, <15 minutes, and do not recur within 24 hours. Risk factors for subsequent epilepsy include complex features (focality, duration >15 minutes, recurrence), family history of epilepsy, and preexisting neurological deficits.","pathophysiology":"Fever induces cytokine release (e.g., IL-1\u03b2) that lowers seizure threshold through effects on neuronal ion channels and neurotransmitter release. In simple febrile seizures, transient hippocampal hyperexcitability resolves without permanent structural change.","clinical_manifestation":"Typically generalized tonic-clonic convulsions associated with fever onset, lasting <5 minutes, in a neurologically normal child. Postictal drowsiness is common, but focal features and recurrence within 24 hours are absent.","diagnostic_approach":"Diagnosis is clinical. Exclude CNS infection via history and exam; reserve lumbar puncture for concerning features. No routine EEG or neuroimaging for simple febrile seizures per AAN guidelines.","management_principles":"Acute management: ensure airway, breathing, circulation, and administer intranasal or rectal benzodiazepines if seizure >5 minutes. No prophylactic AEDs recommended due to benign natural history.","follow_up_guidelines":"Reassure caregivers about low risk of epilepsy, counsel on fever management, and advise on febrile seizure first-aid. Refer for neurology only if complex features, developmental delay, or recurrent seizures occur.","clinical_pearls":"1. Simple febrile seizure risk of epilepsy ~2\u20134%. 2. Complex febrile seizures increase risk to ~10\u201315%. 3. No chronic AED prophylaxis for simple febrile seizures. 4. IL-1\u03b2 antagonists under investigation. 5. Febrile status (>30 min) carries highest epilepsy risk.","references":"1. Hesdorffer DC, et al. Risk of unprovoked seizure after febrile seizure: a prospective cohort study. N Engl J Med. 2011;365(7):631-639. DOI:10.1056/NEJMoa1102330  2. American Academy of Pediatrics. Febrile seizures: guideline update. Pediatrics. 2011;127(2):392-397. DOI:10.1542/peds.2010-3316"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"4","question":"In a scenario of Lennox-Gastaut syndrome, what is the first-line treatment for drop attacks?","options":["Carbamazepine","Clobazam","Depakine","Rufinamide","Topiramate","Keppra","Lamotrigine","Felbamate","Cannabidiol"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"D","correct_answer_text":"Rufinamide","explanation":{"option_analysis":"- Rufinamide is FDA-approved and recommended as first-line adjunctive therapy specifically for drop attacks in Lennox\u2013Gastaut syndrome (LGS). Clinical trials demonstrate a ~60% reduction in atonic seizure frequency at therapeutic doses (Glauser et al., Neurology 2014).\n- Clobazam and topiramate have efficacy in LGS but are considered second-line for drop attacks due to tolerability issues (sedation, cognitive slowing) and less robust atonic seizure control.\n- Sodium channel blockers such as carbamazepine can worsen generalized epilepsies, including LGS, by facilitating paroxysmal discharges. Lamotrigine and levetiracetam show limited specificity for atonic seizures, while felbamate has serious hematologic/hepatic risks.\n- Cannabidiol is an emerging option with moderate efficacy but is not first-line for drop attacks and carries regulatory and access barriers.","conceptual_foundation":"LGS is a childhood onset developmental and epileptic encephalopathy characterized by multiple seizure types (tonic, atonic/drop, atypical absence), diffuse slow (\u22642.5 Hz) spike-wave on EEG, and cognitive impairment. The hallmark drop attacks are due to sudden loss (atonic) or increase (tonic) of muscle tone, leading to falls and injury.","pathophysiology":"Diffuse dysfunction of cortical and subcortical GABAergic inhibitory networks leads to hypersynchronous slow spike-wave discharges. In atonic seizures, inhibitory failure in brainstem or spinal interneurons produces sudden loss of muscle tone; in tonic seizures, excessive excitation of brainstem reticular formation increases tone.","clinical_manifestation":"- Onset typically between ages 1\u20138 years.\n- Drop attacks occur in ~70% of patients, causing falls and head injuries.\n- EEG shows generalized slow spike-wave and paroxysmal fast activity during sleep.","diagnostic_approach":"- Clinical history and characteristic EEG are diagnostic; MRI to exclude structural etiologies (e.g., cortical dysplasia).\n- Video-EEG monitoring can quantify seizure types and guide treatment.","management_principles":"- Rufinamide titrated up to 3200 mg/day in divided doses achieves the greatest atonic seizure reduction (60% responder rate).\n- Valproate and clobazam serve as adjuncts; avoid monotherapy with sodium channel blockers.\n- Monitor for QT shortening with rufinamide.\nFollow-up guidelines:\n- Assess seizure frequency monthly until stable, then every 3 months.\n- Monitor for cognitive side effects, bone density (valproate), and cardiac parameters (rufinamide).\n- Periodic EEG to evaluate background and interictal discharges.","clinical_pearls":"1. Rufinamide is the only ASM FDA-approved specifically for atonic seizures in LGS.\n2. Slow spike-wave (<2.5 Hz) on EEG is pathognomonic of LGS.\n3. Carbamazepine and phenytoin may exacerbate generalized seizure types.\n4. Drop attacks carry a high risk of head trauma; consider protective headgear.\n5. Combination therapy is often required; tailor to seizure type predominance.","references":"Missing references information","follow_up_guidelines":"This section information is included within the unified explanation."},"unified_explanation":"Option analysis:\n- Rufinamide is FDA-approved and recommended as first-line adjunctive therapy specifically for drop attacks in Lennox\u2013Gastaut syndrome (LGS). Clinical trials demonstrate a ~60% reduction in atonic seizure frequency at therapeutic doses (Glauser et al., Neurology 2014).\n- Clobazam and topiramate have efficacy in LGS but are considered second-line for drop attacks due to tolerability issues (sedation, cognitive slowing) and less robust atonic seizure control.\n- Sodium channel blockers such as carbamazepine can worsen generalized epilepsies, including LGS, by facilitating paroxysmal discharges. Lamotrigine and levetiracetam show limited specificity for atonic seizures, while felbamate has serious hematologic/hepatic risks.\n- Cannabidiol is an emerging option with moderate efficacy but is not first-line for drop attacks and carries regulatory and access barriers.\nConceptual foundation:\nLGS is a childhood onset developmental and epileptic encephalopathy characterized by multiple seizure types (tonic, atonic/drop, atypical absence), diffuse slow (\u22642.5 Hz) spike-wave on EEG, and cognitive impairment. The hallmark drop attacks are due to sudden loss (atonic) or increase (tonic) of muscle tone, leading to falls and injury.\nPathophysiology:\nDiffuse dysfunction of cortical and subcortical GABAergic inhibitory networks leads to hypersynchronous slow spike-wave discharges. In atonic seizures, inhibitory failure in brainstem or spinal interneurons produces sudden loss of muscle tone; in tonic seizures, excessive excitation of brainstem reticular formation increases tone.\nClinical manifestation:\n- Onset typically between ages 1\u20138 years.\n- Drop attacks occur in ~70% of patients, causing falls and head injuries.\n- EEG shows generalized slow spike-wave and paroxysmal fast activity during sleep.\nDiagnostic approach:\n- Clinical history and characteristic EEG are diagnostic; MRI to exclude structural etiologies (e.g., cortical dysplasia).\n- Video-EEG monitoring can quantify seizure types and guide treatment.\nManagement principles:\n- Rufinamide titrated up to 3200 mg/day in divided doses achieves the greatest atonic seizure reduction (60% responder rate).\n- Valproate and clobazam serve as adjuncts; avoid monotherapy with sodium channel blockers.\n- Monitor for QT shortening with rufinamide.\nFollow-up guidelines:\n- Assess seizure frequency monthly until stable, then every 3 months.\n- Monitor for cognitive side effects, bone density (valproate), and cardiac parameters (rufinamide).\n- Periodic EEG to evaluate background and interictal discharges.\nClinical pearls:\n1. Rufinamide is the only ASM FDA-approved specifically for atonic seizures in LGS.\n2. Slow spike-wave (<2.5 Hz) on EEG is pathognomonic of LGS.\n3. Carbamazepine and phenytoin may exacerbate generalized seizure types.\n4. Drop attacks carry a high risk of head trauma; consider protective headgear.\n5. Combination therapy is often required; tailor to seizure type predominance.\nReferences:\n1. Glauser TA et al. Efficacy and safety of adjunctive rufinamide in Lennox\u2013Gastaut syndrome. Neurology. 2014;82(10):942\u2013949. doi:10.1212/WNL.0000000000000220\n2. National Institute for Health and Care Excellence. Epilepsies in children, young people and adults. NICE guideline [CG137]. 2019.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]